Vista Partners Initiates Coverage on Raptor Pharmaceuti...( LOS ANGELES Oct. 9 /- Vista Partn...),Health

LOS ANGELES, Oct. 9 /PRNewswire/ -- Vista Partners announced today that it has initiated coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP). "Raptor's management team was pivotal in getting two drugs approved and creating stockholder value while at BioMarin Pharmaceutical, a $2.4B biotech company and we believe they will do it again with Raptor," stated Ross Silver, Director of Research at Vista Partners. Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. For more information and to download the report; please visit the Vista Partners website at http://www.vistap.com.

About Raptor:

Raptor Pharmaceuticals Corp.'s (the "Company") sole business is its 100% ownership of Raptor Pharmaceutical Inc., a development stage biotechnology company which bioengineers novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins. The Company's preclinical programs target cancer, neurodegenerative disorders, infectious diseases and osteoporosis. HepTide(TM) utilizes engineered RAP-based peptides conjugated to drugs to target their delivery to the liver. In neurodegenerative diseases, engineered RAP peptides called NeuroTrans(TM) are currently undergoing evaluation at Stanford University in cell culture and preclinical models for their ability to enhance the transport of molecules from blood to brain. In osteoporosis, Raptor is testing the ability of WntTide(TM), which are Mesd and engineered Mesd-based peptides and act through LRP5, a known determinant of bone density, to combat osteoporosis and increase bone density. In an effort to protect its novel approach, Raptor currently has five patent applications in review in the U.S., and countries in Europe and Asia, as well as two provisional patent applications licensed from
'/>"/>